

World Journal of *Psychiatry*

World J Psychiatry 2022 September 19; 12(9): 1115-1267



Contents

Monthly Volume 12 Number 9 September 19, 2022

EDITORIAL

- 1115 Suicidal behavior-advances in clinical and neurobiological research and improvement of prevention strategies

Sobanski T, Peikert G, Kastner UW, Wagner G

OPINION REVIEW

- 1127 Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms

Zhang S, Ma Y

REVIEW

- 1141 Underlying mechanisms of mindfulness meditation: Genomics, circuits, and networks

Gu YQ, Zhu Y

- 1150 Depressive disorder and antidepressants from an epigenetic point of view

Šalamon Arčan I, Kouter K, Videtič Paska A

ORIGINAL ARTICLE

Case Control Study

- 1169 Delayed improvements in visual memory task performance among chronic schizophrenia patients after high-frequency repetitive transcranial magnetic stimulation

Du XD, Li Z, Yuan N, Yin M, Zhao XL, Lv XL, Zou SY, Zhang J, Zhang GY, Li CW, Pan H, Yang L, Wu SQ, Yue Y, Wu YX, Zhang XY

- 1183 Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition

Minic Janicijevic S, Jovanovic IP, Gajovic NM, Jurisevic MM, Debnath M, Arsenijevic NN, Borovcanin MM

Observational Study

- 1194 Associations between social support and anxiety during the COVID-19 lockdown in young and middle-aged Israelis: A cross-sectional study

Xi Y, Elkana O, Jiao WE, Li D, Tao ZZ

SYSTEMATIC REVIEWS

- 1204 Psychotic symptoms in bipolar disorder and their impact on the illness: A systematic review

Chakrabarti S, Singh N

- 1233 Mental health impact on Black, Asian and Minority Ethnic populations with preterm birth: A systematic review and meta-analysis

Delanerolle G, Zeng YT, Phiri P, Phan T, Tempest N, Busuulwa P, Shetty A, Raymont V, Rathod S, Shi JQ, Hapangama DK

LETTER TO THE EDITOR

- 1255** Sodium selenite may be not the optimal speciation as an effective therapy for arsenic-induced anxiety-/depression-like behavior
Ren XH, Wang XX, He LP
- 1258** Beneficial for mental health, exercise more or less?
Yan WJ, Zhang F, Ouyang H, Xing CQ, Liu WZ
- 1261** Magnesium may be an effective therapy for Alzheimer's disease
Lei DY, Sun J
- 1264** Why do we not reverse the path? Stress can cause depression, reduction of brain-derived neurotrophic factor and increased inflammation
Claro AE, Palanza C, Mazza M, Rizzi A, Tartaglione L, Marano G, Muti-Schuenemann G, Rigoni M, Muti P, Pontecorvi A, Janiri L, Sani G, Pitocco D

ABOUT COVER

Editorial Board Member of *World Journal of Psychiatry*, Giampaolo Perna, MD, PhD, Chairman, Professor, Department of Biomedical Sciences, Humanitas University, Milan 20090, Italy. giampaolo.perna@hunimed.eu

AIMS AND SCOPE

The primary aim of *World Journal of Psychiatry* (WJP, *World J Psychiatry*) is to provide scholars and readers from various fields of psychiatry with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJP mainly publishes articles reporting research results and findings obtained in the field of psychiatry and covering a wide range of topics including adolescent psychiatry, biological psychiatry, child psychiatry, community psychiatry, ethnopsychology, psychoanalysis, psychosomatic medicine, etc.

INDEXING/ABSTRACTING

The WJP is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJP as 3.500; IF without journal self cites: 3.313; 5-year IF: 7.380; Journal Citation Indicator: 0.62; Ranking: 89 among 155 journals in psychiatry; and Quartile category: Q3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Yu-Xi Chen*; Production Department Director: *Xu Guo*; Editorial Office Director: *Jia-Ping Yan*.

NAME OF JOURNAL

World Journal of Psychiatry

ISSN

ISSN 2220-3206 (online)

LAUNCH DATE

December 31, 2011

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Rajesh R Tampi, Ting-Shao Zhu, Panteleimon Giannakopoulos

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2220-3206/editorialboard.htm>

PUBLICATION DATE

September 19, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/gerinfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/gerinfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/gerinfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Magnesium may be an effective therapy for Alzheimer's disease

Dao-Yun Lei, Jie Sun

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Chakrabarti S, India;
Van Den Bossche MJA, Belgium

Received: May 10, 2022

Peer-review started: May 10, 2022

First decision: June 11, 2022

Revised: June 13, 2022

Accepted: September 1, 2022

Article in press: September 1, 2022

Published online: September 19, 2022



Dao-Yun Lei, Jie Sun, Department of Anesthesiology, Zhongda Hospital Southeast University, Nanjing 210009, Jiangsu Province, China

Corresponding author: Jie Sun, PhD, Doctor, Professor, Research Scientist, Department of Anesthesiology, Zhongda Hospital Southeast University, No. 87 Dingjiaqiao, Nanjing 210009, Jiangsu Province, China. dgsunjie@hotmail.com

Abstract

Magnesium deficiency in serum or the brain of Alzheimer's disease (AD) patients has been shown to be associated with AD. Current research suggests that supplementing or restoring magnesium may be a novel approach to AD treatment. However, the physiological properties of magnesium make such treatment difficult. It is undeniable that magnesium may be an effective therapy for AD.

Key Words: Alzheimer's disease; Magnesium; Therapy; Deficiency

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Magnesium deficiency in serum or the brain of Alzheimer's disease (AD) patients has been shown to be associated with AD. However, the physiological properties of magnesium make such treatment difficult. Undeniably, magnesium may be an effective therapy for AD.

Citation: Lei DY, Sun J. Magnesium may be an effective therapy for Alzheimer's disease. *World J Psychiatry* 2022; 12(9): 1261-1263

URL: <https://www.wjgnet.com/2220-3206/full/v12/i9/1261.htm>

DOI: <https://dx.doi.org/10.5498/wjp.v12.i9.1261>

TO THE EDITOR

Alzheimer's disease (AD) is the most common dementia characterized by the decline of cognitive function in the elderly. The accumulation of β -amyloid plaques and the existence of neurofibrillary tangles are the pathological bases for the dysfunction of various signaling pathways in the nervous system[1]. Since the pathogenic mechanism of AD is still not clear, its treatment approaches are unlikely to be meaningfully effective. Several approved drugs ameliorate some of the symptoms of AD, but no

current interventions can modify the underlying disease mechanisms[2,3]. We read the interesting article by Xiong *et al*[4], which was published in *World Journal of Psychiatry*. Their study found that magnesium L-threonate alleviated neuronal apoptosis by inhibiting oxidative stress, especially in the hippocampus. Although the research work revealed a potential scheme for the treatment of AD, we still believe that some views deserve further consideration and look forward to receiving the reply from the authors.

Admittedly, magnesium is one of the most abundant cations in the intracellular environment after potassium. Mg^{2+} is tightly regulated and kept at basal levels by normal Mg^{2+} intake, absorption, and metabolism under physiological conditions. Total magnesium levels in the hippocampus of AD patients decreased by 18% compared with that of normal subjects[5]. Although the presence of magnesium deficiency in patients with AD is notable, its severity may be underestimated. The concentration of serum Mg^{2+} in healthy people ranges from 0.70 mM to 1.05 mM[6]. Mg^{2+} deficiency is generally determined by measuring the total serum Mg^{2+} concentration, but it cannot accurately reflect the concentration of magnesium in the human body. Most Mg^{2+} is stored in bone, muscle, and soft tissue, and the proportion of serum Mg^{2+} is very low. Even if the human body is in a serious state of Mg^{2+} depletion, serum magnesium may also be in the normal range. Although the magnesium concentration in AD patients is reduced, the degree of deficiency cannot be accurately evaluated. It is not only difficult to evaluate magnesium deficiency, but also a reasonable supplement of magnesium. Slutsky *et al* found that following long-term magnesium supplementation, Mg^{2+} concentration in cerebrospinal fluid only increases by 15%[7]. On one hand, systemic magnesium is closely regulated by renal function. On the other hand, the blood-brain barrier separates the brain from the daily fluctuations of blood magnesium. Hippocampal synapses are very sensitive to small changes in extracellular Mg^{2+} concentration (increasing the concentration of magnesium by 15% can increase the synaptic density by 50%)[8]. Encouragingly, compared with other Mg^{2+} compounds (such as magnesium chloride, magnesium citrate, and magnesium gluconate), dietary intake of magnesium L-threonate could significantly increase Mg^{2+} levels in the brain[4]. Therefore, restoring brain magnesium may be a potential way to treat cognitive impairment in patients with AD.

Conclusion

In summary, magnesium may be a novel therapeutic strategy for AD-induced cognitive impairment. However, numerous clinical studies are still needed to confirm the clinical application of magnesium.

FOOTNOTES

Author contributions: Lei DY and Sun J contributed to the conception of the research; Lei DY and Sun J wrote the letter and contributed to the revision of the letter; all authors approved the final manuscript for submission.

Conflict-of-interest statement: There are no conflicts of interest to report.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Dao-Yun Lei 0000-0001-9105-9021; Jie Sun 0000-0002-8647-7867.

S-Editor: Chen YL

L-Editor: Wang TQ

P-Editor: Chen YL

REFERENCES

- 1 **Falter A**, Van Den Bossche MJA. How non-rapid eye movement sleep and Alzheimer pathology are linked. *World J Psychiatry* 2021; **11**: 1027-1038 [PMID: 34888171 DOI: 10.5498/wjp.v11.i11.1027]
- 2 **Masters CL**, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer's disease. *Nat Rev Dis Primers* 2015; **1**: 15056 [PMID: 27188934 DOI: 10.1038/nrdp.2015.56]
- 3 **Salehipour A**, Bagheri M, Sabahi M, Dolatshahi M, Boche D. Combination Therapy in Alzheimer's Disease: Is It Time? *J Alzheimers Dis* 2022; **87**: 1433-1449 [PMID: 35491785 DOI: 10.3233/JAD-215680]
- 4 **Xiong Y**, Ruan YT, Zhao J, Yang YW, Chen LP, Mai YR, Yu Q, Cao ZY, Liu FF, Liao W, Liu J. Magnesium-L-threonate exhibited a neuroprotective effect against oxidative stress damage in HT22 cells and Alzheimer's disease mouse model.

- World J Psychiatry* 2022; **12**: 410-424 [PMID: 35433327 DOI: 10.5498/wjp.v12.i3.410]
- 5 **Andrási E**, Páli N, Molnár Z, Kösel S. Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. *J Alzheimers Dis* 2005; **7**: 273-284 [PMID: 16131728 DOI: 10.3233/jad-2005-7402]
 - 6 **de Baaij JH**, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. *Physiol Rev* 2015; **95**: 1-46 [PMID: 25540137 DOI: 10.1152/physrev.00012.2014]
 - 7 **Slutsky I**, Abumaria N, Wu LJ, Huang C, Zhang L, Li B, Zhao X, Govindarajan A, Zhao MG, Zhuo M, Tonegawa S, Liu G. Enhancement of learning and memory by elevating brain magnesium. *Neuron* 2010; **65**: 165-177 [PMID: 20152124 DOI: 10.1016/j.neuron.2009.12.026]
 - 8 **Li W**, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, Xiong W, Ren C, Liu XG, Chui D, Liu G. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model. *Mol Brain* 2014; **7**: 65 [PMID: 25213836 DOI: 10.1186/s13041-014-0065-y]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

